It has previously been shown that inhibition of CD26 (DPPIV/ dipeptidylpeptidase IV) peptidase activity improves homing of hematopoietic stem cells (HSCs) to the bone marrow and increases engraftment efficiency. Here, we demonstrate that treatment of retrovirally transduced mouse bone marrow cells with the tri-peptide Diprotin A (Ile-Pro-Ile), a specific inhibitor of CD26, significantly enhances engraftment of retrovirally transduced HSCs. Hematopoietic stem cells (HSCs) are excellent targets for gene therapy because of their capacity for self-renewal and multiple-lineage differentiation potential. 1 Genetic modification of autologous HSCs has the potential to be used for the treatment of several inborn errors and for manipulation of immune responses without the need for allogeneic bone marrow transplantation which can cause immunoincompetence and graft versus host disease. [2] [3] [4] [5] [6] However, problems associated with gene transfer into HSCs, engraftment efficiency following transplantation, and long-term gene expression continue to plague the field. 7, 8 Inefficient gene transfer typically results in transplantation of a small number of genetically modified HSCs which have to compete with a greater number of unmodified HSCs for bone marrow niches in order to undergo engraftment. Efforts to improve engraftment could provide a means to increase the ability of modified HSCs to engraft, leading to development of a greater frequency of cells expressing transduced genes of interest. Enhancing engraftment of genetically modified HSCs is therefore an important part of improving HSC gene therapy.
CD26 (DPPIV/dipeptidylpeptidase IV) is a membrane associated dipeptidase expressed on the surface of a variety of cells including HSCs.
9,10 CD26 cleaves dipeptides from the N-terminus of proteins containing an X-proline or X-alanine motif, including the chemoattractant CXCL12 (SDF-1a). 11 Signaling through CXCR4 following CXCL12 binding is critically involved in controlling trafficking and homing of HSCs to their bone marrow niches. 12, 13 Cleavage of the N-terminal dipeptide from CXCL12 by CD26 prevents its interaction with CXCR4 on HSCs thereby overcoming the chemotatic properties of CXCL12. 9, 14, 15 In recent studies, it has been shown that CD26 plays a critical role in homing of HSCs to their bone marrow niche. Inhibition of CD26 activity on bone marrow HSCs using the tri-peptide Diprotin A (Ile-ProIle), a specific inhibitor of CD26, 9 significantly increased the homing and engraftment of HSCs following transplantation into lethally irradiated mice. 16 Based on these studies, we hypothesized that CD26 inhibition could play an important role in HSC gene therapy by allowing for more efficient engraftment of limited numbers of genetically modified cells.
Here, we investigated whether inhibition of CD26 activity following retroviral transduction of bone marrow can be used to enhance the engraftment of limiting numbers of retrovirally transduced hematopoietic progenitors. Treatment of retrovirally transduced bone marrow cells with Diprotin A prior to transplantation significantly improved the efficiency at which limiting numbers of bone marrow cells expressing a retrovirally transduced allogeneic MHC class I gene engrafted in lethally irradiated recipients. Importantly, the level of engraftment achieved was sufficient to allow for the induction of tolerance to the product of the transduced MHC class I gene. Our data demonstrate that inhibition of CD26 may be important for achieving physiologically relevant levels of engraftment using limited numbers of genetically modified bone marrow HSCs. ). 4 To examine the capacity of Diprotin A to enhance engraftment of retrovirally transduced cells, bone marrow was harvested from B10.AKM mice treated 7 days prior with 150 mg/kg 5-fluorourcil and transduced with VSV-G envelope pseudotyped viruses carrying the gene encoding H-2K b (VSV-Kb viruses) as described. 17 Treatment with 5-fluorouracil was used to increase the fraction of quiescent early hematopoietic progenitor cells in the bone marrow. 6 bone marrow cells, of which approximately 30% are transduced. 17 To assess whether CD26 inhibition could be used to increase the efficiency of engraftment of limited numbers of retrovirally transduced bone marrow, therefore, we used a dose of bone marrow that is below the threshold level need to allow for detection of K b on bone marrow-derived cells by flow cytometry. The observed increase in the frequency of cells expressing K b in the blood of mice receiving Diprotin A-treated bone marrow could be the result of either enhanced HSC engraftment, or improved engraftment of committed progenitors such as common lymphoid progenitors. 21, 22 To address this issue, we next analyzed whether Diprotin A-treated transduced cells were capable of multilineage (Figure 3a) . As expected, we were unable to detect expression of K b on the surface of cells from control mice receiving HBSS-treated bone marrow (Figure 3a) . Similar results were observed at 8 and 12 weeks after reconstitution (data not shown). Cells expressing K b were detected in all lymphoid tissues analyzed from mice reconstituted with Diprotin A-treated VSV-Kb-transduced bone marrow at 20 weeks after reconstitution ( To further analyze whether multilineage expression of K b following reconstitution with Diprotin A-treated bone marrow resulted from engraftment of transduced HSCs, we performed secondary reconstitution experiments. Groups of mice which exhibited expression of K b on bone marrow-derived cells following reconstitution with Diprotin A-treated bone marrow were killed 28 weeks after reconstitution. Bone marrow cells were harvested from these mice and then transplanted into the secondary B10.AKM recipients that received 11-Gy whole body irradiation 1 day prior. Expression of K b was readily detectable on the surface of multiple hematopoietic cells lineages in blood of secondary recipients 8 weeks after bone marrow transplantation (Figure 3b ). These data suggest that Diprotin A treatment permitted engraftment of transduced HSCs.
Enhanced engraftment using Diprotin A allows for the induction of tolerance to K b using minimal numbers of transduced bone marrow progenitors
We have previously shown that reconstitution of mice with syngeneic bone marrow cells transduced with VSVKb virus results in tolerance to K b , permitting survival of H-2K congenic B10.MBR skin allografts. 17 Therefore, we examined whether engraftment of small numbers of retrovirally transduced bone marrow cells using Diprotin A treatment was sufficient to induce tolerance to K b . B10.AKM mice were lethally irradiated and reconstituted with 5 Â 10 5 VSV-Kb-transduced bone marrow cells treated with Diprotin A or HBSS as described above. At 7 weeks after reconstitution, mice in each group received both a B10.MBR (H-2K Figure  4 ). These mice retained the ability to rapidly reject third party B10.BR skin grafts (Figure 4) , indicating that the inability to reject their B10.MBR graft was not due to immunoincompetence. In contrast, mice receiving VSVKb-transduced bone marrow treated with HBSS rejected both their B10.MBR and B10.BR skin grafts with similar kinetics (n ¼ 10, Figure 4) . Mice receiving Diprotin Atreated VSV-Kb-transduced bone marrow in which K b expressing cells were not detected also rapidly rejected both their B10.MBR and B10.BR skin grafts (n ¼ 4, Figure  4 ). These data suggest that inhibition of CD26 activity reduces the number of hematopoietic progenitors that must be transplanted to induce tolerance in conditioned recipients.
The ability to achieve hematopoietic reconstitution using small numbers of HSCs currently limits the application of HSC transplantation as a treatment for many disorders. In the context of HSC gene therapy, inefficient gene transfer methods compound this issue because only a relatively small portion of HSCs carry the gene of interest. Genetically modified cells must then compete with a larger number of unmodified HSCs for niches in the bone marrow, which may affect their ability to engraft and contribute to hematopoiesis. The chemoattractant CXCL12 (SDF-1a) plays a critical role in HSC homing to bone marrow niches and engraftment, and is Inhibition of CD26 to improve transduced HSC engraftment C Tian et al regulated through proteolytic cleavage by the dipeptidase CD26. 9, [12] [13] [14] [15] [23] [24] [25] Inhibition of CD26 activity using Diprotin A, thereby preventing cleavage of the Nterminal dipeptide of CXCL12, has been shown to significantly increase the ability of limiting numbers of HSCs to engraft in lethally irradiated mice. 9, 16 In this study, we examined whether inhibition of CD26 could be used to improve the engraftment of limiting numbers of retrovirally transduced bone marrow cells.
To address whether CD26 inhibition could be used to improve engraftment of retrovirally transduced bone marrow cells, we utilized a model, we developed involving retroviral mediated transfer of an allogeneic MHC class I gene, H-2K b . 4 In this model, lethally irradiated mice are reconstituted with 4 Â 10 6 retrovirally transduced bone marrow cells, of which approximately 30% have been transduced. 17 Reconstitution of mice with this number of transduced bone marrow cells (approximately 1. were observed in all lymphoid tissues analyzed and the frequency of cells expressing K b was stable over-time. We were also able to demonstrate expression of K b on hematopoietic cells in secondary transfer receipients. These data strongly suggest that CD26 inhibition improved the efficiency of transduced HSC engraftment.
We have previously shown that reconstitution of lethally irradiated mice with syngeneic bone marrow cells expressing the retrovirally encoded H-2K b gene can be used to induce tolerance to skin allografts expressing K b . 4 In these studies, the frequency of cells expressing Based on our data, we suggest that inhibition of CD26 activity can significantly enhance the ability of small numbers of retrovirally transduced HSCs to engraft and give rise to progeny expressing the transduced gene of interest. Our data confirm and extend the findings of Christopherson et al. 16 showing that in addition to bone marrow transplantation, inhibition of CD26 peptidase activity by Diprotin A can also be used to significantly improve engraftment of retrovirally transduced syngeneic hematopoietic progenitors. The finding that incubation of bone marrow in vitro with Diprotin A during transduction affects engraftment in vivo suggests that the effects of CD26 inhibition occur relatively quickly after injection of bone marrow into conditioned recipients, and that chemoattractant signaling at early time points is critical for efficient bone marrow engraftment. In the field of HSC gene therapy, the use of CD26 Inhibition of CD26 to improve transduced HSC engraftment C Tian et al inhibition as part of a transplantation regimen could decrease the number of cells needed to achieve a threshold level of engraftment allowing the development of a significant frequency of cells expressing transduced genes in the periphery. Recently, many CD26 inhibitors have been discovered. [26] [27] [28] [29] [30] [31] [32] [33] These inhibitors have been used in a variety of disease settings. 27, 29, [32] [33] [34] It would be interesting to know whether these CD26 inhibitors could be used to enhance the homing and engraftment of genetically modified hematopoietic cells. In particular, it will be of interest to determine how these agents affect the engraftment of modified HSCs in hosts receiving clinically relevant nonmyeolablative conditioning. ), and B10.BR (H-2 k ) mice were purchased from the Jackson Laboratory, Bar Harbor, ME. Mice were housed using micro-isolator conditions in autoclaved cages and maintained on irradiated feed and autoclaved acidified drinking water. All sentinel mice housed in the same colony were viral antibody-free. Mice (6-to 8-weekold) were used in all experiments. All experiments involving were conducted in accordance with institutional guidelines.
Mice

Retrovirus
Construction and production of the VSV-Kb virus used in this study has been described previously. 17 The titer of the retroviral supernatant used in these studies was 4 Â 10 6 infectious particles per milliliter.
Bone marrow harvest, transduction, Diprotin A treatment and transplantation Donor B10.AKM mice were treated with 5-fluorouracil (5-FU) (150 mg/kg). Seven days later, bone marrow was harvested, and transduced with VSV-Kb virus as described previously. 17 Following transduction, cells were washed in HBSS and then resuspended in either HBSS containing 5 mM Diprotin A (Peptides International, Louisville, KY) or HBSS alone for 15 min at 371C. The cells were then washed three times and injected into the tail vein of B10.AKM mice that received 11-Gy whole body irradiation 1 day prior. All bone marrow transplants were performed within 30 min of Diprotin A treatment.
Secondary bone marrow transplantation
At 28 weeks after reconstitution, bone marrow cells were harvested from primary recipients and then transplanted into secondary B10.AKM mice that received 11-Gy whole body irradiation 1 day prior. Each secondary recipient mouse received 3 Â 10 7 bone marrow cells.
Antibodies and flow cytometry
Monoclonal antibodies specific for H-2K b (AF6-88.5), CD4 (RM4-5), CD8 (53-6.7), B220 (RA3-6B2), CD11b (Mac-1, M1/70), CD49b, (NK cells, DX5) and CD11c (HL3) were obtained from BD PharMingen (San Diego, CA). Cell surface staining and flow cytometry was performed as described previously. 17 Expression of K b on the surface of bone marrow-derived cells was evaluated as described in Tian et al.
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Skin grafting
Tail skin grafting was performed and evaluated as described previously. 17 
